Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform

Key Takeaway: Javelin Biotech and Pfizer have announced a significant publication regarding clinical pharmacokinetic predictions. The study utilizes a multi-tissue chip platform, showcasing advancements in drug development methodologies. This collaboration highlights the ongoing efforts to enhance predictive models in clinical settings.